Novavax (NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue expectations. The company ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.

If passed, anyone who provides or administers a gene-based vaccine to another person would face a penalty of $500 per violation.

The current COVID-19 vaccine is 33% effective at preventing emergency department or urgent care visits among adults of all ages. It also is 45% to 46% effective at preventing hospitalizations in older ...

Case data has become a less meaningful indicator of COVID-19 activity since individual cases are being reported in a very limited basis by health care settings and laboratories. The same is true for ...

The Iowa Senate bill alters a proposal that would have penalized administering gene-based vaccines including the COVID-19 ...

Effectiveness of 2024-25 COVID-19 vaccination against a COVID-19–associated ED/UC visit was 33% (95% confidence interval [CI] ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The split will allow WBD to take advantage of "broader market opportunities" as they arise, CEO David Zaslav told analysts.

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...